A recent study published in Diabetology and Metabolic Syndrome provided insights about the beneficial role of probiotic formulations in improving lipid profiles and glycemic control in type 2 diabetes patients.
The prevalence of type 2 diabetes mellitus is increasing, making it a global concern. Certain studies demonstrated the role of gut microbiota in the development of disease, pointing out the benefits of probiotics for glycemic control. This study aimed to examine the effectiveness of various probiotic therapies in managing T2DM.
Researchers included 62 randomized controlled studies from Cochrane, Web of Science, and PubMed, and the studies were evaluated using the Cochrane risk of bias tool 2. HbA1c level was measured at baseline and after intervention (baseline HbA1c 5.71% to 9.5%). R program version 4.2.1was used to calculate the mean difference (MD).
Results revealed that there was the greatest reduction in fasting plasma glucose (FPG) by the combination of Lactococcus lactis W58, Lactobacillus acidophilus W37, Lactococcus lactis W19, Bifidobacterium bifidum W23, Lactobacillus casei W56, Bifidobacterium lactis W52, Lactobacillus brevis W63, and Lactobacillus salivarius W24. Yogurt containing Bifidobacterium Bb12, Cucurbita ficifolia, and Lactobacillus acidophilus La5 showed the greatest reduction in HbA1c [MD = − 1.59]. Yeast containing Saccharomyces cerevisiae appeared as the best intervention for total cholesterol.
Featured
Off
Page Content
#ffffff
Anonymous user
On
Authenticated user
On
Premium
On
Paid / Sponsored
On
Key highlights
- Probiotics targeting gut microbiota show promise as supportive therapies for glycemic control in type 2 diabetes mellitus (T2DM).
- The most effective probiotic combo for lowering fasting plasma glucose includes multiple strains like Bifidobacterium bifidum W23 and Lactobacillus acidophilus W37 (MD = -73.50 mg/dL).
- Yogurt containing Lactobacillus acidophilus La5, Bifidobacterium Bb12, and Cucurbita ficifolia achieved the most significant HbA1c reduction (MD = -1.59%).
- Saccharomyces cerevisiae yeast significantly reduced total cholesterol (MD = -43.67 mg/dL).
- Despite promising results, variability in probiotic types, dosages, and study designs requires cautious interpretation and further research.
Source
Allam, A.R., Helal, M.B., Alhateem, M.S. et al. Network meta-analysis of randomized controlled trials evaluating the effectiveness of various probiotic formulations in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 17, 265 (2025). https://doi.org/10.1186/s13098-025-01841-2
Thumbnail
Speciality
Currency
Sub Speciality
Sub Sub Speciality
Short Description
Meta-analysis shows probiotic formulations improve blood sugar and cholesterol in type 2 diabetes, with specific strains offering targeted metabolic benefits.
User Segments
Release Date
Featured Order
0
Is Paid
0